EFFICACY OF IVABRADINE (CORAXAN) IN PATIENTS WITH POST-COVID TACHYCARDIA

Abstract

The coronavirus pandemic showed not only an increase in levels of excess morbidity and mortality in the acute phase of an infection, but also the presence of persisting symptoms four weeks after the onset of the disease. A review of the international studies on the prevalence and diversity of the manifestation of the post-covid syndrome is presented. The data on such manifestations of post-covid syndrome as postural orthostatic tachycardia syndrome is being accumulated.In the trial, there were observed 27 patients with post-covid postural orthostatic tachycardia syndrome. All of them were treated by Ivabradine (Coraxan) in dose of 5 mg twice a day per os - during 8 weeks. The results of Holter monitoring in these patients showed a significant decrease of heart rate during the treatment with Coraxan. Functional indicators of the left ventricle contractility (such as EF, EDV and ESV) also were improved. There were revealed clinical improvements including the reduction of heart palpitation, increase of the quality of life and perfection of mood.The author puts forward the future prospects of using Ivabradine (Coraxan) in treatment of post-covid postural orthostatic tachycardia on the basis of literature data and her own clinical experience.